Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

@article{Hillier2009PreclinicalEO,
  title={Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.},
  author={S. Hillier and K. Maresca and F. Femia and J. Marquis and C. Foss and N. Nguyen and C. Zimmerman and J. Barrett and W. Eckelman and M. Pomper and J. Joyal and J. Babich},
  journal={Cancer research},
  year={2009},
  volume={69 17},
  pages={
          6932-40
        }
}
Prostate-specific membrane antigen (PSMA) is expressed in normal human prostate epithelium and is highly up-regulated in prostate cancer. We previously reported a series of novel small molecule inhibitors targeting PSMA. Two compounds, MIP-1072, (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid, and MIP-1095, (S)-2-(3-((S)-1carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid, were selected for further evaluation. MIP-1072 and MIP-1095 potently inhibited… Expand

Paper Mentions

Interventional Clinical Trial
This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic… Expand
ConditionsProstate Cancer
InterventionDrug
Interventional Clinical Trial
This is a single arm, open label study of up to 24 high risk prostate cancer patients scheduled for prostatectomy and/or pelvic lymph node dissection. Patients receive a single IV… Expand
ConditionsProstate Cancer
InterventionDrug
Interventional Clinical Trial
This is a single arm, open label study of up to 24 prostate cancer patients scheduled for prostatectomy and/or pelvic lymph node dissection. Patients receive a single IV dose of… Expand
ConditionsProstate Cancer
InterventionDrug
123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase.
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
  • J. Pinto, B. Suffoletto, +6 authors W. Heston
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
...
1
2
3
4
5
...